The U.S. Food and Drug Administration approved Tecentriq as a standalone therapy for an advanced form of lung cancer.
The American Lung Association announced a $25 million initiative to support the fight against COVID-19, as well as future viral pandemics.
The U.S. Food and Drug Administration approved Boehringer Ingelheim’s Ofev (nintedanib) for patients with chronic fibrosing interstitial lung diseases (ILD) with a progressive phenotype.
The U.S. Food and Drug Administration granted Breakthrough Therapy designation to Genentech’s Esbriet as a potential treatment for adults with unclassifiable interstitial lung disease (uILD) as the Roche subsidiary looks to expand the drug’s indications.
Shares of Insmed skyrocketed after the company posted positive Phase II results for INS1007 as a potential treatment for adults with non-cystic fibrosis bronchiectasis (NCFBE).
Pneumonia killed more than 800,000 babies and young children during 2018 – or one child every 39 seconds – despite being curable and mostly preventable, global health agencies said.
Bayer, Brigham and Women’s Hospital, and Massachusetts General Hospital launched a joint laboratory to research new drugs to treat chronic lung diseases.
The U.S. Food and Drug Administration gave the thumbs-up to Boehringer Ingelheim’s Ofev (nintedanib) for systemic sclerosis-associated interstitial lung disease.
Tubingen, Germany-based CureVac entered a collaboration research agreement with Yale University to focus on lung therapies.
Boehringer Ingelheim’s SENSCIS Phase III clinical trial met the primary endpoint for nintedanib in patients with SSc-ILD.